15

20

CLAIMS

What is claimed is:

A non-human transgenic mammal, progeny or embryo thereof which has integrated into its genome DNA comprising a regulatory sequence of a mammalian nestin gene operably linked to a gene coding for a fluorescent protein wherein the gene coding for the fluorescent protein is expressed in multipotent stem and progenitor cells of the non-human transgenic mammal,

progeny or embryo thereof.

- 2. The non-human transgenic mammal, progeny or embryo thereof of Claim 1 wherein the gene coding for the fluorescent protein is selectively expressed in multipotent stem and progenitor cells of the non-human transgenic mammal or progeny thereof.
- 3. The non-human transgenic mammal, progeny or embryo thereof of Claim 1 wherein the gene coding for the fluorescent protein is expressed in neural stem and progenitor cells of the non-human transgenic mammal or progeny thereof.
 - 4. The non-human transgenic mammal, progeny or embryo thereof of Claim 1 wherein the mammal is mouse.
- 5. The non-human transgenic mammal, progeny or embryo thereof of Claim 1 wherein the regulatory sequence of the mammalian nestin gene is obtained from rat nestin gene.

Docket No.: CSHL99-05

5

- 6. The non-human transgenic mammal, progeny or embryo thereof of Claim 1 wherein the regulatory sequence includes a second intron sequence of the mammalian nestin gene.
- 7. The non-human transgenic mammal, progeny or embryo thereof of Claim 1 wherein the regulatory sequence includes a promoter.
 - 8. The non-human transgenic mammal, progeny or embryo thereof of Claim 7 wherein both the promoter and the regulatory sequence are obtained from the same mammalian nestin gene.

A method of producing a non-human transgenic mammal which expresses a fluorescent protein in multipotent stem and progenitor cells, comprising:

- (a) introducing into a fertilized egg of a non-human mammal, DNA comprising a regulatory sequence of a mammalian nestin gene operably linked to a gene coding for a fluorescent protein that is expressed in multipotent stem and progenitor cells of the non-human mammal;
- (b) introducing the fertilized egg of (a) into a non-human mammal of the same species;
- (c) allowing the non-human mammal to produce progeny which are non-human transgenic mammals; and
- (d) selecting non-human mammal progeny of (c) whose multipotent stem and progenitor cells express the fluorescent gene.
- 10. The method of Claim 9 wherein the gene coding for a fluorescent protein is selectively expressed in multipotent stem and progenitor cells.
 - The method of Claim 9 wherein the gene coding for a fluorescent protein is expressed in neural stem and progenitor cells.

10 mm

15

:0

20

11



- The method of Claim 9 wherein the non-human transgenic mammal is mouse. 12.
- The method of Claim 9 wherein the the regulatory sequence of the mammalian 13. nestin gene is obtained from rat nestin gene.
- The method of Claim 9 wherein the regulatory sequence comprises a second 14. intron sequence of the mammalian nestin gene.
 - 15. The method of Claim 14 wherein the regulatory sequence further includes a promoter.
 - The method of Claim 15 wherein both the promoter and the regulatory sequence 16. are obtained from the same mammalian nestin gene.
- A non-human transgenic mammal produced by the method of Claim 9. 10 17.
 - An expression construct comprising a promoter sequence, a gene-coding for 18. green fluorescent protein and a regulatory sequence present in the second intron of said-mammalian nestin gene.

A method for measuring a multipotent stem and progenitor cell population in an animal organ or region thereof, comprising: measuring cells which fluoresce from the organ or region thereof of a nonhuman transgenic mammal which has integrated into its genome DNA comprising:

a regulatory sequence operably linked to a gene coding for a fluorescent protein, 20 wherein the gene coding for the fluorescent protein is expressed in multipotent stem and progenitor cells of the non-human transgenic mammal, wherein the cells which fluoresce are multipotent stem and progenitor cells.

Sub By,

- 20. The method of Glaim-19 wherein the gene coding for a fluorescent protein is selectively expressed in multipotent stem and progenitor cells.
- 21. The method of Claim 19 wherein the gene coding for a fluorescent protein is expressed in neural stem and progenitor cells.

The non-human transgenic mammal, progeny or embryo thereof of Claim 19 wherein the regulatory sequence includes a second intron sequence of the mammalian nestin gene.

- 23. The non-human transgenic mammal, progeny or embryo thereof of Claim 19 wherein the regulatory sequence further includes a promoter.
- The non-human transgenic mammal, progeny or embryo thereof of Claim 23 wherein both the promoter and the regulatory sequence are obtained from the same mammalian nestin gene.
- 25. A method of obtaining primary, noncultured, multipotent stem and progenitor cells comprising isolating cells which express a marker/reporter protein from a non-human transgenic mammal, progeny or embryo thereof which has integrated into its genome DNA comprising a regulatory sequence of a mammalian nestin gene operably linked to a gene coding for the marker/reporter protein wherein the gene coding for the marker/reporter protein is expressed in multipotent stem and progenitor cells of the non-human transgenic mammal, progeny or embryo thereof.
 - 26. A method of obtaining primary, noncultured, multipotent stem and progenitor cells comprising isolating fluorescent cells from a non-human transgenic mammal, progeny or embryo thereof which has integrated into its genome DNA

Docket No.: CSHL99-05 -31-

comprising a regulatory sequence of a mammalian nestin gene operably linked to a gene coding for a fluorescent protein wherein the gene coding for the fluorescent protein is expressed in multipotent stem and progenitor cells of the non-human transgenic mammal, progeny or embryo thereof.

5 27. The method of Claim 26 wherein the gene coding for the fluorescent protein is selectively expressed in multipotent stem and progenitor cells of the non-human transgenic mammal, progeny or embryo thereof.

28. The method of Claim 26 wherein the gene coding for the fluorescent protein is expressed in neural stem and progenitor cells of the non-human transgenic mammal, progeny or embryo thereof.

29. The method of Claim 26 wherein the regulatory sequence comprises a second intron sequence of the mammalian nestin gene.

- 30. The method of Claim 26 wherein the regulatory sequence further includes a promoter.
- 15 31. The method of Claim 30 wherein both the promoter and the regulatory sequence are obtained from the same mammalian nestin gene.
 - 32. The method of Claim 26 further comprising identifying and/or isolating genes expressed in said isolated fluorescent cells.
- The method of Claim 26 further comprising identifying and/or isolating proteins
 expressed in said isolated fluorescent cells.

10

Docket No.: CSHL99-05 -32-

Ē

:0

10

15

20

34. The method of Claim 26 further comprising identifying and/or isolating cell-specific surface antigens expressed on said isolated fluorescent cells.

- 35. The method of Claim 26 further comprising transplanting said isolated fluorescent cells into a live animal or a viable embryo.
- 5 36. The method of Claim 26 wherein fluorescent cells are isolated by fluorescent activated cell sorting.
 - 37. A method for assessing a compound's ability to promote multipotent stem and progenitor cell differentiation, comprising:
 - (a) contacting live multipotent stem and progenitor cells, which have integrated into their genome DNA comprising a regulatory sequence of a mammalian nestin gene operably linked to a gene coding for a marker/reporter protein wherein the gene coding for the marker/reporter protein is expressed in multipotent stem and progenitor cells, with a compound to be assessed;
 - (b) determining a marker/reporter protein measurement of the live cells of a) in the presence of the compound; and
 - (c) comparing the marker/reporter protein measurement of b) to the marker/reporter protein measurement of live control cells; wherein a decrease or absence of marker/reporter protein measurement of the live cells in the presence of the compound compared to the marker/reporter protein measurement of the live control cells is indicative of the compound's ability to promote multipotent stem and progenitor cell differentiation.
 - 38. The method of claim 37 wherein the marker/reporter protein is a fluorescent protein and the marker/reporter protein measurement is fluorescence.

15

202)

- 39. The method of Claim 37 wherein the gene coding for a fluorescent protein is selectively expressed in multipotent stem and progenitor cells.
- 40. The method of Claim 38 wherein the gene coding for a fluorescent protein is expressed in neural stem and progenitor cells.
- 5 41. The method of Claim 37 wherein the compound is a therapeutic agent.
 - 42. The method of Claim 37 wherein the differentiation is to neural stem and progenitor cells.
 - 43. A method for assessing a compound's toxicity to multipotent stem and progenitor cells, comprising:
 - (a) contacting live stem and progenitor cells, which have integrated into their genome DNA comprising a regulatory sequence of a mammalian nestin gene operably linked to a gene coding for a marker/reporter protein, wherein the gene coding for the marker/reporter protein is expressed in multipotent stem and progenitor cells, with a compound to be assessed;
 - (b) determining live cells expressing the marker/reporter protein in the presence of the compound; and
 - (c) comparing the live cells expressing the marker/reporter protein of b) to live, control cells expressing the marker/reporter protein;
- wherein a decrease or absence of live cells expressing the marker/reporter protein in the presence of the compound compared to the live control cells expressing the marker/reporter protein is indicative of the compound's toxicity to multipotent stem and progenitor cells.

:Д

10

15

20

Docket No.: CSHL99-05 -34-

- 44. The method of Claim 43 wherein the marker/reporter protein is a fluorescent protein and cells expressing the marker/reporter protein are fluorescent cells.
- 45. The method of Claim 44 wherein the gene coding for a fluorescent protein is selectively expressed in multipotent stem and progenitor cells.
- 5 46. The method of Claim 44 wherein the gene coding for fluorescent protein is expressed in neural stem and progenitor cells.
 - 47. A method for assessing a compound's ability to promote differentiation of totipotent cells into multipotent stem and progenitor cells, comprising:
 - (a) contacting live totipotent stem and progenitor cells, which have integrated into their genome DNA comprising a regulatory sequence of a mammalian nestin gene operably linked to a gene coding for a marker/reporter protein, wherein the gene coding for the marker/reporter protein is expressed in multipotent stem and progenitor cells;
 - (b) determining a marker/reporter protein measurement of the live cells of a) in the presence of the compound; and
 - (c) comparing the marker/reporter protein measurement of b) to marker/reporter protein measurement of control cells;

wherein an increase of marker/reporter protein measurement in the presence of the compound compared to the marker/reporter protein measurement of control cells is indicative of the compound's ability to promote differentiation of totipotent cells into multipotent stem and progenitor cells.

48. The method of Claim 46 wherein the marker/reporter protein is a fluorescent protein and the marker/reporter protein measurement is fluorescence.

Sub O3

- 49. The method of Claim 48 wherein the gene coding for a fluorescent protein is selectively expressed in multipotent stem and progenitor cells.
- 50. The method of Claim 48 wherein the compound is a therapeutic agent.

add B5>